Valneva SE ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $205M+16.8% YoYTTM through 31 Dec 2025
Net Income -$135.2MTTM through 31 Dec 2025
Free Cash Flow -$67.3MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 38.7% |
| Operating Margin | -47.0% |
| Net Margin | -66.0% |
Returns
-108.5%ROE
-28.9%ROA
Balance Sheet Health
Debt / Equity1.95x
Current Ratio2.38x
Net Debt$97.6M
Cash & Equivalents$109.7M
Quality Metrics
Piotroski F-Score3 / 9
FCF Margin-32.8%
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $174.7M
Diluted EPSFY2025: $-0.68
Dividend
No dividend
Capital Allocation
Capex Intensity2.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Proprietary Products | $138.7M | +9.0% | |
| Distribution | $19.2M | -42.3% | View detailsPlanned wind-down of third-party sales to less than 5% of total sales by 2026/2027. |
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.